Conclusion: Our study confirmed the extraordinary efficacy of DAAs outside clinical trials.
2
DAAs improve liver function especially in those with decompensated disease who achieve SVR.
3
Patients were treated with DAAs according to the physicians' preference.
4
Conclusions: Our study shows that in Italian penitentiary settings DAAs treatment is feasible and effective.
5
Results: We enrolled 142 incarcerated people treated with DAAs.
6
Currently, second generation direct acting antivirals (DAAs) promise clearance of infection in most of patients.
7
It was by now past mid-1990 and the ABC was about to give DAAS its own series.
8
Using propensity-score matched patients, we found that DAAs improved overall survival and reduced the risk of hepatic decompensation.
9
Objectives: To evaluate safety and efficacy of RBV in the era of DAAs in chronic HCV Egyptian patients.
10
Of 94 patients, 93 provided home supply of DAAs during hospitalization.
11
We evaluated the effect of DAAs on kidney function and the factors associated with an improvement or worsening.
12
More importantly, the high cost associated with the DAAs restricts their accessibility to most parts of the world.
13
Our initial analysis suggests that those receiving DAAs are likely, in the long term, to follow a similar course.
14
Here we present the results of the first analysis carried out on data of Lazio clinical network for DAAs.
15
For Jehan Daas was old and a cripple, and Nello was but a child; and Patrasche was their dog.
16
Conclusion: Networks-based approaches greatly increase understanding of HCV transmission and will inform the implementation of treatment as prevention using DAAs.